Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt AR., Jackson R., Cicconi S., Polydoros F., Yap C., Dodd J., Bickerstaff M., Stackpoole M., Khan UT., Carruthers S., Oates M., Lin K., Coupland SE., Menon G., Kalakonda N., McCarthy H., Bloor A., Schuh A., Duncombe A., Dearden C., Fegan C., Kennedy B., Walewska R., Marshall S., Fox CP., Hillmen P.